Table 3.

Cases with both conventional pancreatic ductal adenocarcinoma and undifferentiated carcinoma components: results of KRAS FISH and KRAS allelic peak height evaluation on sequencing electropherogram

Case no.	Histology	KRAS mutation	Peak height on SE	KRAS FISH
				KRAS/CEP12	% Of cells with hyperploidy	% Of cells with monosomy
1	Undiff.	p.G12D	MA =WT	1.1	41.2%	N
	PDAa	p.G12D	MA<WT	1.23	N	N
2	Undiff.	p.G12D	MA =WT	2.02	N	46.7%
	PDA	p.G12D	MA =WT	2.43	N	68.3%
3	Undiff.	p.G12V	MA =WT	2.38	N	N
	PDA	n.t.	n.t.	3.19	N	N
4	Undiff.	p.G12D	MA>WT	2.51	N	N
	PDA	n.t.	n.t.	1.29	50%	N
5	Undiff.	p.G12V	MA>WT	4.36	64.5%	N
	PDA	n.t.	n.t.	1.24	N	47.6%
6	Undiff.	p.G12V	MA =WT	9.75	N	N
	PDAb	p.G12V	MA<WT	1.28	N	N
7	Undiff.	p.G12D	MA<WT	1.02	N	N
	PDAa	p.G12D	MA<WT	1.03	N	N
8	Undiff.	p.G12D	MA<WT	3.16	62.9%	N
	PDA	p.G12D	MA<WT	1.75	88.5%	N
9	Undiff.	p.G12D	MA<WT	1.1	53.8%	N
	PDA	p.G12D	MA<WT	1.08	11.5%	N
10	Undiff.	p.G12D	MA>WT	1.6	40%	N
	PDAb	n.t.	n.t.	1.19	23.3%	N
11	Undiff.	p.G12R	MA<WT	1.16	46.3%	N
	PDA	n.t.	n.t.	1.1	56.3%	N

Abbreviations: FISH, fluorescence in situ hybridization; MA, mutant allele; N, normal (<40% of cells with hyperploidy or monosomy); n.t., not tested; PDA, well-differentiated component; SE, sequencing electropherogram; Undiff., undifferentiated component; WT, wild-type allele. The proportion (and size) of the PDA component ranged from 1% (0.3 cm) to 40% (3.6 cm).

^aThe PDA component arose from a mucinous cystadenocarcinoma.

^bThe microscopic focus of PDA arose from an intraductal papillary mucinous neoplasm.